Concepedia

Elizabeth A. Lakota

EA

Statistics

Publications

10

Citations

361

H-Index

10

Active since

2013

Affiliations

Institute for Clinical Pharmacodynamics (United States)(Current)

Paratek Pharmaceuticals (United States)

University of Wisconsin–Madison

Cidara Therapeutics (United States)

JMI Laboratories

Elizabeth A. Lakota is an author at Institute for Clinical Pharmacodynamics (United States) specializing in pharmacology, pharmacokinetics, and pharmacokinetics of antimicrobials.

Publications per year

2013–2023

10

Publications

10

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

Bianca Weinstock‐Guttman, Robert Zivadinov, Dana Horáková et al. · Journal of Neurology Neurosurgery & Psychiatry · 2013 · 124 citations

, , +15

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Justin Bader, Elizabeth A. Lakota, Shawn D. Flanagan et al. · Antimicrobial Agents and Chemotherapy · 2018 · 44 citations · Full text

, , +17

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models

Catharine C. Bulik, Ólanrewaju O. Okusanya, Elizabeth A. Lakota et al. · Antimicrobial Agents and Chemotherapy · 2016 · 42 citations · Full text

, , +14

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Elizabeth A. Lakota, Justin Bader, Voon Ong et al. · Antimicrobial Agents and Chemotherapy · 2017 · 38 citations · Full text

, , +17

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

Elizabeth A. Lakota, Voon Ong, Shawn D. Flanagan et al. · Antimicrobial Agents and Chemotherapy · 2018 · 35 citations · Full text

, , +17

1–5 of 10